Charles River Laboratories International EBIT

The latest EBIT for CRL is $520M as of September 2026. That compares with $89M in the prior-year period — up 484.4% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Charles River Laboratories International's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRL's EBIT moved from $89M to $520M — a 484.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Charles River Laboratories International's operating scale or balance-sheet position.

Against Healthcare companies, CRL currently prints $520M for EBIT, while the sector average sits near $99B. That is roughly 99.5% below the sector mean. Large gaps often invite a closer look at Charles River Laboratories International's growth, margins, and balance sheet.

A EBIT figure of $520M for CRL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting CRL's EBIT ($520M), review year-over-year change from $89M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.